Accordingly, the Consensus Report of the American Diabetes Association recommends prioritizing the use of SGLT2 inhibitors in individuals with stage B HF and in all patients with stages C or D HF, without taking LVEF into consideration [9]. Here, SLC5A2 is linked to diabetes mellitus.